natgillin/translations-raw huggingface dataset:
30x1, 50x1, 90x1 and 100x1 tablet in all-aluminium perforated unit-dose blisters.
30x1, 50x1, 90x1 i 100x1 tableta u perforiranim aluminijskim blisterima djeljivim na jedinične doze.
30°C) in diffused daylight.
30°C) pri difuznoj dnevnoj svjetlosti.
30×1 capsule
30×1 kapsula
30–39 3.0 mg* zoledronic acid
30 – 39 3,0 mg* zoledronatne kiseline
30–60 Every 24 hours, at least 1 day, until healing is achieved.
30 – 60 Svaka 24 sata, najmanje 1 dan, dok se ne postigne zacjeljivanje.
30–60 Repeat infusion every 12 to 24 hours for 3 to 4 days or more until pain and acute disability are resolved.
30 – 60 Ponovite infuziju svakih 12 – 24 sati u razdoblju od 3 do 4 dana ili duže dok ne prestanu bolovi i akutna onesposobljenost.
31 (10.4%)
Ispitanici u kojih
31 03-841 Warszawa
Nicosia
31 60 minutes, half the dose must be taken again.
31-60 minuta, mora se ponovno uzeti polovica doze.
31 December
31. prosinca 2016.
31 December 2016
31. prosinca 2016
31 December 2021.
31. prosinca 2021.
31 hours
31 sat
31 March 2019
31. ožujka 2019.
31 March 2025
do 31. ožujka 2025.
31% (13) (p=0.10b
31% (13) (p=0,10b)
31% (19.9, 43.4) P < 0.001b
31% (19,9; 43,4) P < 0,001b
31% (n = 51)
16% (n = 50) 35% (n = 51)
31% (N=129) had received 1 prior line of therapy (EGFR-TKI treatment only), 69% (N=282) had received 2 or more prior lines.
31% njih (N=129) je primilo 1 prethodnu liniju liječenja (samo inhibitor tirozin kinaze EGFR-a), dok je njih 69% (N=282) primilo 2 ili više prethodnih linija liječenja.
31% had localised prostate cancer
31% s lokaliziranim karcinomom prostate
31% p = 0.002
31% p = 0,002
31-546 Krakow Poland
31-546 Krakov Poljska
31-546 Krakow Poland
31-546 Krakow Poljska
31-546 Krakow Poland
31-546 Krakow, Poljska
31-546 Krakow, Poland
31-546 Krakow, Poljska
31-546 Kraków Poland
31-546 Krakov Poljska
31-546 Kraków Poland
31-546 Krakov, Poljska
31-546 Kraków Poland
31-546 Kraków Poljska
31-546 Kraków Poland
31-546 Kraków Poljska‌
31-546 Kraków, Poland
31-546 Kraków, Poljska
31-546, Krakow Poland
31-546, Krakow Poljska
31-546, Krakow Poland
31-546, Krakow Poljska‌‌
31-546, Krakow,
31-546, Krakow, Poljska
31-546, Krakow, Poland
31-546, Krakow, Poljska
31-60 minutes, half the dose must be taken again.
31-60 minuta, mora se ponovno uzeti polovica doze.
31.0 (18/58)
Remisija bez steroida
31028 Gronau/Leine Germany
31028 Gronau/Leine Njemačka
31057 Toulouse Cedex FRANCE
4, chemin du Calquet 31057 Toulouse Cedex FRANCUSKA
316 d
316d
319 Pinner Road North Harrow Middlesex, HA1 4HF United Kingdom
319, Pinner Road North Harrow Middlesex HA1 4HF Velika Britanija
319 subjects with AK were treated with up to 2 sachets once daily of Imiquimod 3.75% cream, or a matching vehicle cream for two 2-week treatment cycles separated by a 2-week no-treatment cycle.
Liječeno je 319 ispitanika s do 2 vrećice imikvimod 3,75 % kreme jedanput dnevno ili s odgovarajućom kremom od podloge tijekom dvotjednih ciklusa liječenja, odvojenih dvotjednim ciklusom bez liječenja.
319, Pinner Road North Harrow Middlesex HA1 4 HF United Kingdom
319, Pinner Road North Harrow Middlesex HA1 4 HF Velika Britanija
319, Pinner Road North Harrow Middlesex HA1 4 HF United Kingdom
319, Pinner Road North Harrow Middlesex HA1 4HF Velika Britanija
319, Pinner Road North Harrow Middlesex HA1 4HF United Kingdom
319, Pinner Road North Harrow Middlesex HA1 4 HF Velika Britanija
319, Pinner Road North Harrow Middlesex HA1 4HF United Kingdom
319, Pinner Road North Harrow Middlesex HA1 4HF Velika Britanija
319, Pinner Road, Harrow Middlesex HA1 4HF United Kingdom
319, Pinner Road, Harrow Middlesex HA1 4HF Ujedinjeno Kraljvstvo
31st December 2017
31. prosinca 2017.
31st December, 2018
31. prosinca 2018.
31st March 2017
30. rujna 2015.
31st March 2018
31. ožujka 2018.
31st October 2016
31.listopada 2016.
31th December, 2019
31. prosinca 2019.
32 % in trial C/I98-580).
C/I98-580).
32 cases were considered to have scarce information regarding underlying history and concomitant drugs, at least five of them have compatible chronology; but a causal association cannot be excluded in these cases.
Za 32 slučaja smatralo se da sadrže oskudne informacije u vezi s postojećom povijesti bolesti i istodobno primijenjenim lijekovima, a njih barem pet imalo je kompatibilnu kronologiju; ipak, uzročna se povezanost nije mogla isključiti u ovim slučajevima.
32 IU/kg (21;
injekcija,
32 IU/kg (22;
32 IU/kg
32 weeks
32 tjedna
32%; P < .0001
32%; P < 0,0001
32.27 g
32,27 g
32.3 hr) and the clearance was reduced (18.9 versus 27.3 l/hr).
32,3 sata), a klirens je smanjen (18,9 naspram 27,3 l/h).
32.3 hrs) and the clearance was reduced (18.9 versus 27.3 l/hr).
32,3 sata), a klirens je smanjen (18,9 naspram 27,3 l/h).
32.4 (30.1, NR)
32,4 (30,1; ND)
32.4 g*
32,4g
32.5 to < 40
32,5 do <40
32.6 to 34.4
32,6 do 34,4
32.9L/min p<0.001 (24.8, 41.1)
32,9 l/min p<0,001 (24,8; 41,1)
32004 data.
3Podaci iz 2004. g.
326 cattle received Metacam given as an injection together with antibiotic therapy whilst 326 cattle received a dummy injection and antibiotic therapy.
Otopinu Metacam od 5 mg/ml za injekciju i antibiotsku terapiju primilo je 326 goveda, dok je drugih 326 goveda primilo injekciju bez djelatne tvari i antibiotsku terapiju.
327 patients completed at least 5 years of long-term follow-up and only 3 out of
Najmanje 5 godina dugotrajnog praćenja dovršilo je 327 bolesnika, a samo su 3 od
327 patients undergoing hip fracture surgery treated for 3 weeks following an initial prophylaxis of 1 week
u 327 bolesnika nakon operacije prijeloma kuka koji su nakon početne jednotjedne profilakse liječeni tijekom 3 tjedna
327 patients who had been treated with NRTIs but not with PIs or NNRTIs.
U ispitivanje 020 uključeno je 327 bolesnika koji su već primali NRTI-je, ali ne i inhibitore proteaze ili NNRTI-je.
33 (27, 39)
Placebo +
33 mg) per dose.
33 mg) po dozi.
33 ml/50 ml vial
33 ml/50 ml Staklena bočica
33,140 vaccinated
33 140 cijepljenih
33.0 (18.1 to -)
33,0 (18,1 do -)
33.3L/min p<0.001 (26.5, 40.0)
33,3 l/min p<0,001 (26,5; 40,0)
33.5L/min p<0.001 (22.3, 41.7)
33,5 l/min p<0,001 (22,3; 41,7)
33.6 micrograms
33,6 mikrograma
332 patients who received docetaxel in combination with prednisone or prednisolone (clinically important treatment related adverse events are presented).
332 bolesnika koji su primali docetaksel u kombinaciji s prednizonom ili prednizolonom (prikazani su klinički značajni štetni događaji povezani s liječenjem),
33428 Harsewinkel North Rhine-Westphalia Germany
33428 Harsewinkel North Rhine-Westphalia Njemačka
33565 Carbon-Blanc-Cedex France
33565 Carbon-Blanc-Cedex Francuska
336 tablets
336 tableta
336.0 micrograms
336,0 mikrograma
33720 Tampere Finland
33720 Tampere Finska
33790 Halle/Westfalen Germany
33790 Halle/Westfalen Njemačka
338 Euston Road London NW1 3BT United Kingdom
338 Euston Road London NW1 3BT Ujedinjeno Kraljevstvo
34 subjects (29 with HCV genotype 1a infection and 5 with HCV genotype 1b infection) were enrolled who had not received treatment for HCV infection after transplantation and had a METAVIR fibrosis score of F2 or less.
U ispitivanje je uključeno 34 ispitanika (29 s infekcijom HCV-om genotipa 1a i 5 s infekcijom HCV- om genotipa 1b) koji nakon transplantacije nisu primali liječenje za infekciju HCV-om i koji su imali fibrozu stupnja F2 ili manje po METAVIR ljestvici.
34 to < 35
34 do < 35
34% of the women included in the pivotal study) completed the extension study.
34% žena uključenih u pivotalno ispitivanje) je završilo produžetak ispitivanja.
34%, p<.0055
34%, p<0,0055
34.0
Statistika
34.5 to 36.3
34,5 do 36,3
34.6 (26.4, 43.6)
3,46 (1,90; 6,27); < 0,001a
34.7 (32.7; 36.8) 30.3 (28.7; 33.3) p-value* 0.0033
34,7 (32,7; 36.8) 30,3 (28,7; 33,3)
34.9
DB
340 mg cefovecin
340 mg cefovecina.
340 mg cefovecin (as sodium salt)
340 mg cefovecina (kao natrijeve soli)
340 mg/m2/day, with no interruptions in the absence of dose limiting toxicity.
340 mg/m2/dan Gliveca, bez prekida u odsutnosti toksičnosti vezane uz dozu.
3400 Hillerod DENMARK
3400 Hillerod DANSKA
3400 Hillerød Denmark
3400 Hillerød Danska
3421 TV Oudewater The Netherlands
3421 TV Oudewater Nizozemska 978+310348-565858
3421 TV Oudewater The Netherlands
3421 TV Oudewater Nizozemska \
3421 TV Oudewater The Netherlands
421 TV Oudewater Nizozemska
3421 TV Oudewater THE NETHERLANDS Tel: +31-(0)348-565858 info@levetpharma.com
3421 TV Oudewater THE NETHERLANDS Tel: +31-(0)348-565858 maxx@maxx.ee info@levetpharma.com
3446 GR Woerden The Netherlands
3446 GR Woerden Nizozemska
35 cm Rigid Tip
kruti nastavak duljine 35 cm
35 coated tablets
35 obloženih tableta
35 film-coated tablets
35 filmom obloženih tableta
35 g of mycophenolate mofetil in 110 g powder for oral suspension
35 g mofetilmikofenolata u 110 g praška za oralnu suspenziju
35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months.
U placebom kontroliranim kliničkim ispitivanjima lijeku je bilo izloženo 35 dojenčadi mlađe od 1 godine s parcijalnim napadajima, a samo je njih 13 bilo u dobi <6 mjeseci.
35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months.
U placebom kontroliranim kliničkim ispitivanjima lijeku je bilo izloženo35 dojenčadi mlađe od 1 godine s parcijalnim napadajima, a samo je njih 13 bilo u dobi ˂ 6 mjeseci.
35 mg (0.35 ml) twice daily
35 mg (0,35 ml) dva puta na dan
35 mg for moderate hepatic impairment (from one 50 mg vial)
35 mg pri umjerenom oštećenju funkcije jetre
35 mg for moderate hepatic impairment (from one 50 mg vial) at reduced volume
(iz jedne bočice od 50 mg)
35 tablets
35 tableta
35 ± 3 d
Apiksaban2
35 ± 4 days
35 ± 4 dana
35 g/1 mg once daily
35 g/1 mg jedanput na dan
35 g/1 mg once daily
jedanput na dan
35% (n = 51)
39% (n = 51)
35% increase 1)
35% povećanje 1)
35, 35 x 1, 50, 50 x 1, 56, 56 x 1, 60, 70, 70 x 1, 98 or 98 x1 film-coated tablets.
30 x 1, 35, 35 x 1, 50, 50 x 1, 56, 56 x 1, 60, 70, 70 x 1, 98 ili 98 x 1 filmom obloženih tableta.
35, 56, 70 (2 x 35 multipack) and 70 film-coated tablets.
56, 70 (2 × 35 multipakiranje) i 70 filmom obloženih tableta.
35, 89257 Illertissen Germany
35 , 89257 Illertissen Njemačka
35, 89257 Illertissen Germany
35, 89257 Illertissen Njemačka
35-38, 42-45; 6-MP 60 mg/m2 oral, days 26-46
35-38, 42-45; 6-MP 60 mg/m2 peroralno, dani 26-46
35.0
(tjedni)
35.2 g Monensin sodium (equivalent to 32.4 g monensin).
35,2 g monenzin natrija (odgovara količini od 32,4 g monenzina).
35.2-162 ng/mL (25th-75th percentile range).The dabigatran geometric mean trough concentration, measured at the end of the dosing interval (i.e.
Geometrijska srednja najniža vrijednost koncentracije dabigatrana, mjerena na kraju dozirnog intervala (tj.
35.2-162 ng/mL (25th–75th percentile range).The dabigatran geometric mean trough concentration, measured at the end of the dosing interval (i.e.
Geometrijska srednja najniža vrijednost koncentracije dabigatrana, mjerena na kraju dozirnog intervala (tj.
35.3 (32.2, NR)
35.3 (32.2, ND)
35.3 ± 13.6 % of the administered activity had been excreted into the urine.
35,3 ± 13,6 % aplicirane radioaktivnosti izlučeno je u urin.
35.5 (19.3-NA)
35,5 (19,3-NP)
350 mg (4.4 ml) twice daily
350 mg (4,4 ml) dva puta na dan
350 mg presentation:
Pakovanje od 350 mg:
35039 Marburg Germany
35039 Marburg Njemačka
35041 Marburg GERMANY
35041 Marburg NJEMAČKA
351 adult patients, respectively.
646 odnosno 351 odraslih bolesnika.
3528 BJ Utrecht The Netherlands
NL-3991 RA Houten Nizozemska
3528 BJ Utrecht The Netherlands.
3528 BJ Utrecht Nizozemska
3542 DR Utrecht The Netherlands
3542 DR Utrecht Nizozemska
3542 DR Utrecht, The Netherlands
3542 DR Utrecht, Nizozemska
3550–7100 U1
3550 – 7100 U1
36 blisters (252 tablets)
36 blistera (252 tablete)
36 months 69.1% (63.1-74.7)
36 mjeseci
36 months after the 1st dose N=387
36 mjeseci nakon
36 months.
36 mjeseci
36 p=0.0738
36 p=0,0738
36 patients were evaluable for efficacy.
U 36 pacijenata se je mogla procijeniti djelotvornost.
36 to less than 75
36 do manje od 75
36 years or younger
36 godina ili mlađe
36-month survival (%)
36-mjesečno preživljenje (%)
36.4 to 38.2
36,4 do 38,2
36.9 μg•h/ml, 10.0 ± 3.3 μg/ml and 3.6 ± 3.5 μg/ml, respectively after 300/75 mg/m2 twice daily with nevirapine (n=12).
± 2,9 µg/ml i 3,4 ± 2,1 µg/ml, dok su pri uzimanju oralne otopine lopinavira/ritonavira u dozi od 300/75 mg/m² dvaput na dan s nevirapinom (n=12) iznosile, redom, 85,8 ± 36,9 µg•h/ml, 10,0 ± 3,3 µg/ml i 3,6 ± 3,5 µg/ml.
360 (3 x 120) tablets
360 (3 x 120) tableta
360 (6x60) tablets (multipack)
360 (6x60) tableta (višestruko pakiranje)
360 capsules
360 kapsula
360 film-coated tablets
360 filmom obloženih tableta
360 film-coated tablets
360 filmom obloženih tableta.
360 film-coated tablets.
360 filmom obloženih tableta.
360 hard capsules
360 tvrdih kapsula
360 mcg/0.6 ml
360 mcg/0,6 ml
360 mg selamectin
360 mg selamektina
360 micrograms PRE-FILLED SYRINGES LABEL
NALJEPNICA ZA NAPUNJENU ŠTRCALJKU 360 mikrograma
360 tablets
360 tableta
360 tablets: EU/1/09/579/012
360 tableta: EU/1/09/579/012
360 tablets: EU/1/09/579/018
360 tableta: EU/1/09/579/018
360 tablets: EU/1/09/580/006
360 tableta: EU/1/09/580/006
360 tablets: EU/1/09/580/012
360 tableta: EU/1/09/580/012
360 tablets: EU/1/09/580/018
360 tableta: EU/1/09/580/018
36400 O Porriño Pontevedra, Spain
36400 O Porriño Pontevedra, Španjolska
36400 Porriño SPAIN
36400 Porriño ŠPANJOLSKA
365) of patients on current techniques.
365) bolesnika liječenih postojećim tehnikama.
366 sustained responders relapsed during the study.
366 bolesnika s trajnim virološkim odgovorom doživjela relaps tijekom ispitivanja.
3663
P<0
37 (10.2)
Pad
37 cats received Metacam and 39 cats received carprofen (another NSAID) by subcutaneous (under the skin) injection immediately after induction of anaesthesia.
Ukupno 37 mačaka primilo je lijek Metacam, a 39 mačaka primilo je karprofen (drugi NSAID) supkutanom (potkožnom) injekcijom odmah nakon početka anestezije.
37 GBq yttrium-90
37 GBq izotopa itrij-90
37 Hollands Road Haverhill, Suffolk CB9 8PU United Kingdom
37 Hollands Road Haverhill, Suffolk CB9 8PU Ujedinjeno Kraljevstvo
37.0%
N/P
37.5 mg hard capsules
Tvrde kapsule od 37,5 mg
37.5% vs 0%
37,5% vs 0
37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No.
37/2010 navedeno da određivanje MRL nije nužno, ili se smatra da se na njih ne primjenjuju odredbe Uredbe (EZ) br.
37/2010 indicates that no MRLs are required.
37/2010 navedeno da određivanje MRL nije nužno.
37/380 (9.7%)
PRIMIJE- NJEN UZ
37081 Göttingen Germany
37081 Göttingen Njemačka
3732 CN De Bilt Netherlands
3732 CN De Bilt Nizozemska
374 102 600
Tel.: +40 374 102 600
375 micrograms of romiplostim.
325 mikrograma romiplostima.
375 micrograms of romiplostim.
375 mikrograma romiplostima.
375 milligram PREZISTA + 50 milligram ritonavir twice a day
375 miligrama lijeka PREZISTA + 50 miligrama ritonavira, dva puta na dan
37530 Pocé-sur-Cisse BELGIUM FRANCE
37530 Pocé-sur-Cisse BELGIJA FRANCUSKA
378 meters and 326 meters respectively; fewer patients were Class I (1/277, 0.4 %) or IV (9/277, 3 %) at baseline.
Manji broj bolesnika je na početku ispitivanja imao bolest funkcionalnog stupnja I (1/277, 0.4%) ili IV (9/277, 3%).
38 mm (1.5 inch) 22 gauge
38 mm i 22 gaugea
38% at least 1 Gd+ lesion at baseline 92% ≥9 T2 lesions baseline
38% s najmanje 1 Gd+ lezijom na početku 92% ≥9 T2 lezija na početku
38-month data Myeloid blast crisis (n=260)
Studija 0102 38-mjesečni podaci
38.3 to 40.1
38,3 do 40,1
38.5 mcg
38,5 mcg
38.5 micrograms blinatumomab powder in a vial (type I glass) with a stopper (elastomeric rubber), seal (aluminium) and a flip off cap and
38,5 mikrograma blinatumomaba u obliku praška u bočici (staklo tipa I) s čepom (elastomerna guma), zatvaračem (aluminij) i „flip-off“ poklopcem i.
38.58 ng h/ml, and 0.47 ng/ml, respectively.
38,58 ng·h/ml, a Cmin 0,47 ng/ml.
38.58 ng·h/ml, and 0.47 ng/ml, respectively.
38,58 ng·h/ml, a Cmin 0,47 ng/ml.
38.7 mg pyriproxifen, 3,175 mg permethrin
38.7 mg piriproksifena, 3175 mg permetrina
380 milligram (3.8 milliliter)
380 miligrama (3,8 mililitara)
382/1005 (38.0%)
Ocijenjeni broj
39 ml/min/1.73 m2, n=9), and Severe (CrCL < 20 ml/min/1.73 m2, n=3).
< 20 ml/min/1,73 m2, n=3).
39 paediatric asthma patients from 12 to 17 years were randomised to reslizumab 0.3 mg/kg, reslizumab 3 mg/kg or placebo as part of two 52-week exacerbation studies (Studies I and II) and one 16-week lung function study (Study III).
Trideset devet pedijatrijskih bolesnika s astmom u dobi od 12 do 17 godina bilo je randomizirano da prima reslizumab u dozi 0,3 mg/kg, reslizumab u dozi od 3 mg/kg ili placebo u sklopu dva ispitivanja egzacerbacije u trajanju od 52 tjedna (Ispitivanja I i II) i jednog ispitivanja funkcije pluća u trajanju od 16 tjedana (Ispitivanje III).
39% (28.0, 51.2) P < 0.001b
39% (28,0; 51,2) P < 0,001b
39-2.10 Inactivated feline Chlamydophila felis (Cello strain): R.P. 1.69-3.50 Inactivated feline leukaemia virus (61E strain): R.P. 1.45-2.00.
39-2.10 Inaktivirana Chlamydophila felis (soj Cello): R.P. 1.69-3.50 Inaktivirani virus mačje leukemije (soj 61E): R.P. 1.45-2.00
39.0% all grades; 12.6% versus 7.8% Grade 3-4), thrombocytopenia (47.4% versus 33.8% all grades;
32,9%; stupanj 3-4: 12,8% naspram 4,6%), umor (svi stupnjevi: 47,8% naspram 39,0%; stupanj 3-4:
39.7
LOCF
392 (14 packs of 28) hard capsules.
392 (14 pakiranja po 28) tvrde kapsule.
392 (350, 435)
Svi bolesnici
392 anthracycline failure metastatic breast cancer patients, have been performed with docetaxel at the recommended dose and regimen of 100 mg/m² every 3 weeks.
Bolesnici su primali docetaksel u preporučenoj dozi od 100 mg/m2 svaka 3 tjedna.
3922
ARADIGM-HF-u
3930 Hamont-Achel Belgium
3930 Hamont-Achel Belgija
3: adverse reactions noted with increased frequency when bexarotene was administered at a dose of >300 mg/m2/day (compared to administration to CTCL patients at 300 mg/m2/day) in non-CTCL cancer patients.
3: nuspojave zabilježene povećanom učestalošću kad se beksaroten primjenjivao u dozi od >300 mg/m2 na dan (u usporedbi s primjenom doze od 300 mg/m2 na dan bolesnicima s CTCL-om) u onkoloških bolesnika bez CTCL-a.
3: Black handle
3: Crni držač
3: cases of interstitial lung disease (predominantly interstitial pneumonia and eosinophilic pneumonia) have been reported from post-marketing experience with telmisartan
3: slučajevi intersticijske bolesti pluća (uglavnom intersticijska upala pluća i eozinofilna upala pluća) su prijavljeni uz telmisartan iz iskustva nakon stavljanja lijeka u promet
3: December
2021.
3: For further description, please see sub-section “Description of selected adverse reactions”
3 Za dodatni opis, molimo pogledajte odlomak „Opis izabranih nuspojava“
3: For further description, please see sub-section “Description of selected adverse reactions”
3 Za dodatni opis, molimo, pogledajte odlomak „Opis izabranih nuspojava“
3: For further description, please see sub-section”Description of selected adverse reactions”
3 Za dodatni opis, molimo pogledajte odlomak „Opis izabranih nuspojava“
3: For further descriptions, please see sub-section “Description of selected adverse reactions”
3 Za dodatni opis, molimo, pogledajte odlomak „Opis izabranih nuspojava“
3: For further descriptions, please see sub-section”Description of selected adverse reactions”
3 Za dodatni opis, molimo, pogledajte odlomak „Opis izabranih nuspojava“
3: Needle guard activation clips
3: aktivacijske spojnice za štitnik igle
3a Remove the adaptor casing from the vial adaptor and discard.
3a Skinite zaštitni kalup s nastavka za bočicu i bacite ga.
3adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+ in total
3 adsorbiran na aluminijev hidroksid, hidratizirani (Al(OH)3) ukupno 0,5 mg Al3+
3adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+ in total
3 adsorbiran na aluminijev hidroksid, hidratizirani (Al(OH)3) ukupno 0,5 mgAl3+
3adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225 milligrams Al).
3 adsorbiran na amorfni aluminijev hidroksifosfat sulfat adjuvans (0,225 miligrama Al).
3adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225 milligrams Al).
3adsorbiran na adjuvans amorfni aluminijev hidroksifosfat sulfat (0,225 miligrama Al).
3Adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.5 milligrams Al).
3adsorbiran na adjuvans amorfni aluminijev hidroksifosfat sulfat (0,5 miligrama Al).
3adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.5 milligrams Al).
3adsorbiran na amorfni aluminijev hidroksifosfat sulfat adjuvans (0,5 miligrama Al).
3booster factor: ratio of the post-booster geometric mean titre (GMT) and the pre-booster GMT.
3faktor docjepljivanja: omjer između geometrijske srednje vrijednosti titra (GMT) nakon docjepljivanja i prije docjepljivanja.
3booster factor: ratio of the post-booster geometric mean titre (GMT) and the pre-booster GMT.
3faktor docjepljivanja: omjer između srednje geometrijske vrijednosti titra (GMT) nakon docjepljivanja i one prije docjepljivanja.
3booster factor: ratio of the post-booster geometric mean titre (GMT) and the pre-booster GMT.
3Čimbenik docjepljivanja: omjer između geometrijske srednje vrijednosti titra (GMT) nakon docjepljivanja i one prije docjepljivanja.
3Extravasation has been reported very rarely.
3Vrlo rijetko je zabilježena ekstravazacija.
3GOUT = Gout Outcomes and Urate-lowering Therapy
3GOUT = Gout Outcomes and Urate-lowering Therapy (Ishodi gihta i terapija snižavanja urata)
3Infusion related reactions (generalized oedema, bronchospasm, wheezing, laryngeal oedema, angioneurotic oedema, generalized pruritis, anaphylaxis, anaphylactoid reaction)
3reakcije povezane s infuzijom (generalizirani edem, bronhospazam, piskanje, edem larinksa, angioneurotski edem, opći svrbež, anafilaksija, anafilaktoidna reakcija)
3Infusion related reactions (generalized oedema, bronchospasm, wheezing, laryngeal oedema, angioneurotic oedema, generalized pruritus, anaphylaxis, anaphylactoid reaction)
3reakcije povezane s infuzijom (generalizirani edem, bronhospazam, piskanje, edem larinksa, angioneurotski edem, opći svrbež, anafilaksija, anafilaktoidna reakcija)
3Infusion related reactions (hypertension, nausea, rash, pyrexia, pruritus, urticaria, throat irritation, hot flush, hypotension, rhinitis, rigors, tachycardia, fatigue, oropharyngeal pain, peripheral oedema, erythema)
povezane s infuzijom (hipertenzija, mučnina, osip, vrućica, svrbež, urtikarija, iritacija grla, navale vrućine, hipotenzija, rinitis, tresavica, tahikardija, umor, bol u ustima i ždrijelu, periferni edem, eritem)
3Infusion related reactions (hypertension, nausea, rash, pyrexia, pruritus, urticaria, throat irritation, hot flush, hypotension, rhinitis, rigors, tachycardia, fatigue, oropharyngeal pain, peripheral oedema, erythma)
povezane s infuzijom (hipertenzija, mučnina, osip, vrućica, svrbež, urtikarija, iritacija grla, navale vrućine, hipotenzija, rinitis, tresavica, tahikardija, umor, bol u ustima i ždrijelu, periferni edem, eritem)
3M Health Care Limited Derby Road Loughborough
3 M Health Care Limited Derby Road Loughborough
3M Health Care Limited, Derby Road, Loughborough, Leicester, LE11 5SF, United Kingdom.
M Health Care Limited, Derby Road, Loughborough, Leicester, LE11 5SF, Ujedinjeno Kraljevstvo
3NHBA (Neisseria Heparin Binding Antigen), NadA (Neisserial adhesin A), fHbp (factor H binding protein)
3NHBA (Neisseria heparin vezujući antigen), NadA (Neisseria adhezin A), fHbp (faktor H vezujući protein)
3October 1995 to April 20, 1999
3Od listopada 1995. do 20. travnja 1999. g.
3Oedema was reported in 6 – 9% of patients treated with pioglitazone over one year in controlled clinical trials.
3 Edem je bio zabilježen u 6–9% bolesnika liječenih pioglitazonom tijekom jedne godine u kontroliranim kliničkim ispitivanjima.
3produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology.
3proizveden na stanicama kvasca (Saccharomyces cerevisiae) tehnologijom rekombinantne DNA.
3Q 2015
3. tromjesečje 2015.
3rd Airway clearance techniques 4th Quinsair
dornaza alfa tehnike za pročišćavanje dišnih puteva
3rd Appearance
Treći nastup
3rd consecutive event
3. uzastopni dogañaj
3rd Course
tjedan 32
3rd occurrence
pojavljuje se 3. put